Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome

Immunobiology

Volumn 207, Issue 1, 2003, Pages 23-28

  Alves, Jose D ^a,c   Ames, Paul R J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSIDADE LUSÓFONA DE HUMANIDADES E TECNOLOGIAS   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; AUTOANTIBODY; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; STEROID;

ANTIOXIDANT ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; HUMAN; LIPID BLOOD LEVEL; LONG TERM CARE; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0037216946     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00215     Document Type: Review

References (50)

1. Morrow, J., L. Nelson, R. Watts, and D. A. Isenberg. 1999. Systemic Lupus erythemtosus. In: Oxford University Press (2nd ed). Autoimmune Rheumatic Diseases. Oxford, pp. 56-103.
2. Ward, M. M. 1999. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42: 338-346.
3. Hughes, G. R. V., E. N. Harris, and A. E. Gharavi. 1986. The anticardiolipin syndrome. J. Rheumatology 13: 486-489.
4. Schousboe, I. 1985. Beta2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 66: 1086-1091.
5. Lin, K. Y., J. P. Pan, D. L. Yang, K. T. Huang, M. S. Chang, P. Y. Ding, and A. N. Chiang. 2001. Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (beta2-glycoprotein I). Life Sci. 69: 707-719.
6. Mc Neil, H. P., R. J. Simpson, C. N. Chesterman, and S. A. Krilis. 1990. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci., USA 87: 4120-4124.
7. Matsuura, E., Y. Igarashi, T. Yasuda, D. A. Triplett, and T. Koike. 1994. Anticardiolipin antibodies recognize Beta 2-Glicoprotein 1 structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179: 457-462.
8. McIntyre, J. A., D. R. Wagenknecht, and T. Sugi. 1997. Phospholipid binding plasma proteins required for antiphospholipid antibody detection - an overview. Am. J. Reprod. Immunol. 37: 101-110.
9. de Groot, P. G., D. A. Horbach, M. J. Simmelink, E. van Oort, and R. H. Derksen. 1998. Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. Lupus 7 Suppl 2: S32-S36.
10. Triplett, D. A. 1998. Many faces of lupus anticoagulants. Lupus 7 Suppl 2: S18-S22.
11. Ward, M. M., E. Pyun, and S. Studenski. 1995. Causes of death in Systemic Lupus Erythematosus. Long-term followup of an inception cohort. Arthritis Rheum. 38: 1492-1499.
12. Urowitz, M. B., A. A. Bookman, B. E. Koehler, D. A. Gordon, H. A. Smythe, and M. A. Ogryzlo. 1976. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 60: 221-225.
13. Manzi, S., E. N. Meilahn, J. E. Rairie, C. G. Conte, T. A. Medsger, Jr., L. Jansen-McWilliams, R. B. D'Agostino, and L. H. Kuller. 1997. Age-specific incidence rates of myocardial infarction and angina in women with Systemic Lupus Erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145: 408-415.
14. Leung, W. H., K. L. Wong, C. P. Lau, C. K. Wong, and H. W. Liu. 1990. Association between antiphospholipid antibodies and cardiac abnormalities in patients with Systemic Lupus Erythematosus. Am. J. Med. 89: 411-419.
15. Manzi, S., F. Selzer, K. Sutton-Tyrrell, S. G. Fitzgerald, J. E. Rairie, R. P. Tracy, and L. H. Kuller. 1999. Prevalence and risk factors of carotid plaque in women with Systemic Lupus Erythematosus. Arthritis Rheum. 42: 51-60.
16. Svenungsson, E., K. Jensen-Urstad, M. Heimburger, A. Silveira, A. Hamsten, U. de Faire, J. L. Witztum, and J. Frostegard. 2001. Risk factors for cardiovascular disease in Systemic Lupus Erythematosus. Circulation 104: 1887-1893.
17. Glueck, C. J., J. E. Lang, T. Tracy, L. Sieve-Smith, and P. Wang. 1999. Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am. J. Cardiol. 83: 1490-1494, A8.
18. Nityanand, S., C. Bergmark, U. de Faire, J. Swedenborg, G. Holm, and A. K. Lefvert. 1995. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J. Intern. Med. 238: 437-443.
19. Ames, P. R. J., A. Margarita, J. Delgado Alves, C. Tommasino, L. Iannaccone, and V. Brancaccio. 2002. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11: 208-214.
20. MacGregor, A. J., V. B. Dhillon, A. Binder, C. A. Forte, B. C. Knight, D. J. Betteridge, and D. A. Isenberg. 1992. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann. Rheum. Dis. 51: 152-155.
21. Manzi, S. 2000. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology (Oxford) 39: 353-359.
22. Borba, E. F, and E. Bonfa. 1997. Dyslipoproteinemias in Systemic Lupus Erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6: 533-539.
23. Lahita, R. G., E. Rivkin, I. Cavanagh, and P. Romano. 1993. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with Systemic Lupus Erythematosus. Arthritis Rheum. 36: 1566-1574.
24. Delgado, Alves J., P. R. J. Ames, S. Donohue, L. Stanyer, J. Noorouz-Zadeh, C. Ravirajan, and D. A. Isenberg. 2002. Antibodies towards High Density Lipoprotein and Beta-2-Glycoprotein-I are inversely correlated with Paraoxonase activity in Systemic Lupus Erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS). Arthritis Rheum. 46: 2686-2694.
25. Sorenson, R. C., C. L. Bisgaier, M. Aviram, C. Hsu, S. Billecke, and B. N. La Du. 1999. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19: 2214-2225.
26. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.
27. Hyka, N., J. M. Dayer, C. Modoux, T. Kohno, C. K. Edwards III, P. Roux-Lombard, and D. Burger. 2001. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97: 2381-2389.
28. Ames, P. R. J., C. Tommasino, J. Alves, J. D. Morrow, L. Iannaccone, G. Fossati, S. Caruso, F. Caccavo, and V. Brancaccio. 2000. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. Lupus 9: 688-695.
29. Morrow, J. D., and L. J. Roberts. 1996. The isoprostanes. Current knowledge and directions for future research. Biochem. Pharmacol. 51: 1-9.
30. Witztum, J. L. 1994. The oxidation hypothesis of atherosclerosis. Lancet 344: 793-795.
31. Bowie, A., and L. A. O'Neil. 2000. Oxidative stress and nuclear factor-kappa β activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. 59: 13-23.
32. Minami, T., and W. C. Aird. 2001. Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-Kappa B and GATA motifs. Biol. Chem. 276: 47632-47641.
33. Viedt, C., J. Vogel, T. Athanasiou, W. Shen, S. R. Orth, W. Kubler, and J. Kreuzer. 2002. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler. Thromb. Vasc. Biol. 22: 914-920.
34. Ames, P. R. J., J. Alves, I. Murat, D. A. Isenberg, and J. Nourooz-Zadeh. 1999. Oxidative stress in Systemic Lupus Erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 38: 529-534.
35. Mackness, B., R. Hunt, P. N. Durrington, and M. I. Mackness. 1997. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17: 1233-1238.
36. Durrington, P. N., B. Mackness, and M. I. Mackness. 2001. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 473-480.
37. Mackness, B., P. N. Durrington, and M. I. Mackness. 1999. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 353: 468-469.
38. Tomas, M., M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, M. Covas, and J. Marrugat. 2000. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20: 2113-2119.
39. Senti, M., M. Tomas, J. Vila, J. Marrugat, R. Elosua, J. Sala, and R. Masia. 2001. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study. Atherosclerosis 156: 443-449.
40. Lambert, M., A. Boullier, E. Hachulla, J. C. Fruchart, E. Teissier, P. Y. Hatron and P. Duriez. 2000. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 9: 299-300.
41. Vaarala, O. 2000. Antibodies to oxidised LDL. Lupus 9: 202-205.
42. Horkko, S., T. Olee, L. Mo, D. W. Branch, V. L. Woods Jr., W. Palinski, P. P. Chen and J. L. Witztum. 2001. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 103: 941-946.
43. Deguchi, H., J. A. Fernandez, T. M. Hackeng, C. L. Banka and J. H. Griffin. 2000. Cardiolipin is a normal component of human plasma lipoproteins. Proc. Natl. Acad. Sci., USA 97: 1743-1748.
44. Eichner, J. E., L. H. Kuller, M. I. Kamboh, and R. E. Ferrell. 1989. Phenotypic effects of apolipoprotein structural variation on lipid profiles. I. APO H and quantitative lipid measures in the healthy women study. Genet. Epidemiol. 6: 311-318.
45. O'Connell, B. J., and J. Genest Jr. 2001. High-density lipoproteins and endothelial function. Circulation 104: 1978-1983.
46. Abe, H., N. Tsuboi, S. Suzuki, H. Sakuraba, H. Takanashi, K. Tahara, N. Tonozuka, T. Hayashi, and M. Umeda. 2001. Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with Systemic Lupus Erythematosus. J. Rheumatol. 28: 990-995.
47. Dinu, A. R., J. T. Merrill, C. Shen, I. V. Antonov, B. L. Myones, and R. G. Lahita. 1998. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7: 355-360.
48. Nuttall, S. L., S. Heaton, M. K. Piper, U. Martin, M. J. Kendall, and C. Gordon. 2001. Oxidative stress and small dense low-density lipoproteins (LDL) in systemic lupus erythematosus. Rheumatology 40 [Suppl 1], 112.
49. Pratico, D., D. Ferro, L. Iuliano, J. Rokach, F. Conti, G. Valesini, G. A. FitzGerald and F. Violi. 1999. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 93: 3401-3407.
50. Meroni, P. L., E. Raschi, C. Testoni, A. Tincani, G. Balestrieri, R. Molteni, M. A. Khamashta, E. Tremoli, and M. Camera. 2001. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 44: 2870-2878.